<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00031733</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069220 (10M-01-1)</org_study_id>
    <secondary_id>LAC-USC-10M011</secondary_id>
    <secondary_id>LAC-USC-IRB-013030</secondary_id>
    <secondary_id>NCI-5506</secondary_id>
    <nct_id>NCT00031733</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma</brief_title>
  <official_title>A Phase II Randomized Trial of a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With Interleukin-12 With Alum or GM-CSF for Patients With Resected Stages IIB/C, III and IV Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from peptides may make the body build an immune response. Combining&#xD;
      vaccine therapy with interleukin-12 and either alum or sargramostim may kill more tumor&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to compare the effectiveness of combining vaccine therapy&#xD;
      with interleukin-12 and either alum or sargramostim in treating patients who have undergone&#xD;
      surgery for stage II, stage III, or stage IV melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the immune reactivity in patients with resected stage IIB, IIC, III, or IV&#xD;
           melanoma vaccinated with tyrosinase, gp100, and MART-1 peptides emulsified with&#xD;
           Montanide ISA-51 with interleukin-12 and either alum adjuvant or sargramostim (GM-CSF).&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified according to disease stage&#xD;
      (cutaneous stage IIB, IIC, III, and IV vs ocular and mucosal stage III and IV). Patients are&#xD;
      randomized to 1 of 3 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive vaccine with tyrosinase:368-376 (370D)/gp100:209-217&#xD;
           (210M)/MART-1:26-27 (27L) peptides emulsified with Montanide ISA-51 (ISA-51), low-dose&#xD;
           interleukin-12 (IL-12) subcutaneously (SC), and alum adjuvant SC on day 1 of weeks 1, 3,&#xD;
           5, 7, 11, 15, 19, 27, and 53.&#xD;
&#xD;
        -  Arm II: Patients receive peptide vaccine emulsified with ISA-51, high-dose IL-12 SC, and&#xD;
           alum adjuvant SC on day 1 of weeks 1, 3, 5, 7, 11, 15, 19, 27, and 53.&#xD;
&#xD;
        -  Arm III: Patients receive peptide vaccine emulsified with ISA-51 on day 1 and low-dose&#xD;
           IL-12 SC and sargramostim (GM-CSF) SC on days 1-5 of weeks 1, 3, 5, 7, 11, 15, 19, 27,&#xD;
           and 53.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60 patients (20 per treatment arm) will be accrued for this&#xD;
      study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">60</enrollment>
  <condition>Intraocular Melanoma</condition>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MART-1 antigen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gp100 antigen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interleukin-12</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tyrosinase peptide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alum adjuvant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of stage IIB, IIC, III, or IV cutaneous melanoma OR stage III or IV ocular&#xD;
             or mucosal melanoma&#xD;
&#xD;
               -  Resected or rendered disease-free&#xD;
&#xD;
          -  HLA-A2.1-positive by standard cytotoxicity assay&#xD;
&#xD;
          -  Tumor tissue must be available for analysis of gp100 staining and tyrosinase and&#xD;
             MART-1 expression by immunohistochemistry&#xD;
&#xD;
               -  Must be positive for at least 1 antigen&#xD;
&#xD;
          -  Failed, ineligible for, or refused prior interferon alfa&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL&#xD;
&#xD;
          -  No bleeding disorder&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  SGOT/SGPT no greater than 2.5 times normal&#xD;
&#xD;
          -  No coagulation disorder&#xD;
&#xD;
          -  Hepatitis surface antigen B negative&#xD;
&#xD;
          -  Hepatitis C negative&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No major cardiovascular illness&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No major respiratory illness&#xD;
&#xD;
        Immunologic:&#xD;
&#xD;
          -  No prior uveitis&#xD;
&#xD;
          -  No prior autoimmune inflammatory eye disease&#xD;
&#xD;
          -  No immune hemolytic anemia&#xD;
&#xD;
          -  No other active autoimmune disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No major gastrointestinal illness&#xD;
&#xD;
          -  No other malignancy within the past 5 years except squamous cell skin cancer or&#xD;
             carcinoma in situ of the cervix curatively treated at least 30 days ago&#xD;
&#xD;
          -  No major systemic infection (e.g., pneumonia or sepsis)&#xD;
&#xD;
          -  No other major medical illness&#xD;
&#xD;
          -  No prior allergic reaction to Montanide ISA-51 or alum adjuvant&#xD;
&#xD;
          -  No requirement for steroid therapy&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior tyrosinase:368-376 (370D), gp100:209-217 (210M), or MART-1:26-35 (27L)&#xD;
             peptides&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 1 month since prior adjuvant chemotherapy for this disease&#xD;
&#xD;
          -  No concurrent adjuvant chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 1 month since prior radiotherapy for this disease&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 1 month since other prior therapy, including adjuvant therapy, for this&#xD;
             disease&#xD;
&#xD;
          -  No other concurrent therapy, including adjuvant therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey S. Weber, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center and Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>March 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 20, 2014</last_update_submitted>
  <last_update_submitted_qc>May 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>iris melanoma</keyword>
  <keyword>ciliary body and choroid melanoma, small size</keyword>
  <keyword>ciliary body and choroid melanoma, medium/large size</keyword>
  <keyword>extraocular extension melanoma</keyword>
  <keyword>recurrent intraocular melanoma</keyword>
  <keyword>stage II melanoma</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-12</mesh_term>
    <mesh_term>Aluminum Hydroxide</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
    <mesh_term>Aluminum sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

